Endometrial Adenocarcinoma

P1, N=12, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting

P2, N=30, Recruiting, University of Florida | Not yet recruiting --> Recruiting

Endometrial factors can lead to infertility, but the exact molecules involved in endometrial receptivity remain unclear. Human endometrial receptivity is best assessed by determining whether a human blastocyst can attach and implant onto the endometrium of interest. With the use of a human embryo surrogate named BAP-EB, we demonstrated the important roles of CDH1 and CTNND1 in human embryo attachment. In particular, we showed that homophilic binding between trophectodermal CDH1 and epithelial CDH1 was one of the major mediators of the first contact in embryo-maternal interaction. Embryo-derived factors induced apical redistribution of CTNND1 and CDH1 in the EEC. Most importantly, the expression of CDH1 on the apical region of EEC represented endometrial receptivity. The results strengthen our understanding of embryo-maternal interaction in humans, and CDH1 could potentially be used for predicting IVF outcomes, which helps clinicians to better counsel the couples who fail with ART.

This study underscores that the management of suspected malignant transformation of adenomyosis requires multidisciplinary evaluation. More importantly, our findings demonstrate that aggressive treatment should be initiated even without definitive pathological confirmation when clinical suspicion is high. The significance of this work lies in its contribution to recognizing the heterogeneous nature of EC-AIA, urging future research to focus on elucidating molecular mechanisms and developing personalized therapeutic strategies for these aggressive variants.

In this context, the CAP regimen-comprising cyclophosphamide, adriamycin, and cisplatin-has demonstrated superior overall efficacy. Moreover, these tumors seem to be relatively resistant to radiation therapy.

P1, N=58, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Feb 2026 --> Feb 2028

P1, N=17, Terminated, Accent Therapeutics | N=100 --> 17 | Trial completion date: Feb 2027 --> Jan 2026 | Recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Jan 2026; The study was terminated by sponsor based on the adverse event profile.

Moreover, our findings suggest that HER2 status could be a relevant prognostic marker in these malignancies. Traditional anti-HER2 targeted therapies are indicated for HER2-positive patients, while a broader population of patients with HER2-low expression may benefit from novel anti-HER2 antibody-drug conjugates.

Clinical significance: Sister Mary Joseph's nodule (SMJN) represents a rare but important clinical sign of metastatic intra-abdominal or pelvic malignancy, often indicating advanced disease.Clinical awareness: Heightened awareness of umbilical lesions among clinicians is essential, particularly in elderly patients presenting with nonspecific systemic symptoms such as weight loss, asthenia, or abdominal pain.Early diagnosis of SMJN is essential, as it frequently signifies advanced metastatic disease. Prompt recognition allows timely initiation of appropriate therapy or palliative care to optimize patient outcomes.

BRCA1/2 carriers exhibit a 2- to 3-fold higher risk of second primary cancer than non-carriers. Ovarian cancer represents the majority of second primary cancers in BRCA1 carriers, while BRCA2 carriers have a wider spectrum of second primary cancers.

P1, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026

Our findings demonstrate that endometrial sEVs enriched in galectin-3 during the implantation phase promote CT differentiation into ST, underscoring a novel role for sEV-mediated protein delivery in regulating early placental development and suggesting potential diagnostic and therapeutic applications in reproductive medicine.